Limits...
Influence of gender and age on the survival of patients with nasopharyngeal carcinoma.

Xiao G, Cao Y, Qiu X, Wang W, Wang Y - BMC Cancer (2013)

Bottom Line: With a median follow-up of 52 months, the male patients had a significantly unfavorable 5-year OS (70.7% compared to 94.1%, P < 0.001), DPFS (71.5% compared to 87.3%, P = 0.029) and DMFS (77.2% compared to 89.7%, P = 0.036) than the female patients.For patients older than 45, only the 5-year OS (72.2% compared to 96.0%, P = 0.001) was significantly different.We are the first to report that younger male patients were more likely to have distant metastases and exhibited inferior overall survival and disease progression-free survival rates compared to other patients.

View Article: PubMed Central - HTML - PubMed

ABSTRACT

Background: The prognostic value of gender and age in the survival of nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated radiotherapy (IMRT) is unclear. Several studies have suggested a female advantage in the prognosis of solid tumors. We investigated the relationship between gender differences and disease outcome in NPC patients treated with IMRT in South China.

Methods: A total of 299 patients with non-disseminated NPC were analyzed retrospectively. IMRT was delivered with a simultaneous modulated, accelerated radiotherapy boost technique at prescribed doses of 70 Gy/30 fractions/6 weeks to the primary tumor (GTVp) and positive neck nodes (GTVn), 60Gy (2.0 Gy/day) to the clinical target volume (CTV) and upper neck region and 54 Gy (1.8 Gy/day) to the clinically negative low neck. A median boost dose of 9.2 Gy (4-20 Gy) was administered to patients with persistent disease at the primary site.

Results: With a median follow-up of 52 months, the male patients had a significantly unfavorable 5-year OS (70.7% compared to 94.1%, P < 0.001), DPFS (71.5% compared to 87.3%, P = 0.029) and DMFS (77.2% compared to 89.7%, P = 0.036) than the female patients. In patients younger than 45, the male patients had a poorer 5-year OS (66.8% compared to 91.2%, P = 0.008), DPFS (59.9% compared to 91.2%, P = 0.005) and DMFS (66.4% compared to 94.0%, P = 0.004) than the female patients. For patients older than 45, only the 5-year OS (72.2% compared to 96.0%, P = 0.001) was significantly different.

Conclusions: Gender and age are strong independent prognostic factors for NPC in this study. We are the first to report that younger male patients were more likely to have distant metastases and exhibited inferior overall survival and disease progression-free survival rates compared to other patients.

Show MeSH

Related in: MedlinePlus

Survival curves for male and female patients. A. The overall survival curves of male and female. B. The disease progression-free survival curves of male and female. C. The distant metastasis-free survival curves of male and female.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3672024&req=5

Figure 1: Survival curves for male and female patients. A. The overall survival curves of male and female. B. The disease progression-free survival curves of male and female. C. The distant metastasis-free survival curves of male and female.

Mentions: Of all the patients, the male patients had a significantly unfavorable 5-year overall survival (OS) (70.7% compared to 94.1%, P < 0.001, X2 = 16.816), disease progression-free survival (DPFS) (71.5% compared to 87.3%, P = 0.029, X2 = 4.743) and distant metastasis-free survival (DMFS) (77.2% compared to 89.7%, P = 0.036, X2 = 4.383) compared to female patients (Figure 1). The number of local or regional failures was too small to allow meaningful analysis, and the 5-year local progression-free survival (LPFS) (92.9% compared to 95.6%, P = 0.684, X2 = 0.165) and regional progression-free survival (RPFS) (93.6% compared to 98.4%, P = 0.084, X2 = 2.964) were not different between genders.


Influence of gender and age on the survival of patients with nasopharyngeal carcinoma.

Xiao G, Cao Y, Qiu X, Wang W, Wang Y - BMC Cancer (2013)

Survival curves for male and female patients. A. The overall survival curves of male and female. B. The disease progression-free survival curves of male and female. C. The distant metastasis-free survival curves of male and female.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3672024&req=5

Figure 1: Survival curves for male and female patients. A. The overall survival curves of male and female. B. The disease progression-free survival curves of male and female. C. The distant metastasis-free survival curves of male and female.
Mentions: Of all the patients, the male patients had a significantly unfavorable 5-year overall survival (OS) (70.7% compared to 94.1%, P < 0.001, X2 = 16.816), disease progression-free survival (DPFS) (71.5% compared to 87.3%, P = 0.029, X2 = 4.743) and distant metastasis-free survival (DMFS) (77.2% compared to 89.7%, P = 0.036, X2 = 4.383) compared to female patients (Figure 1). The number of local or regional failures was too small to allow meaningful analysis, and the 5-year local progression-free survival (LPFS) (92.9% compared to 95.6%, P = 0.684, X2 = 0.165) and regional progression-free survival (RPFS) (93.6% compared to 98.4%, P = 0.084, X2 = 2.964) were not different between genders.

Bottom Line: With a median follow-up of 52 months, the male patients had a significantly unfavorable 5-year OS (70.7% compared to 94.1%, P < 0.001), DPFS (71.5% compared to 87.3%, P = 0.029) and DMFS (77.2% compared to 89.7%, P = 0.036) than the female patients.For patients older than 45, only the 5-year OS (72.2% compared to 96.0%, P = 0.001) was significantly different.We are the first to report that younger male patients were more likely to have distant metastases and exhibited inferior overall survival and disease progression-free survival rates compared to other patients.

View Article: PubMed Central - HTML - PubMed

ABSTRACT

Background: The prognostic value of gender and age in the survival of nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated radiotherapy (IMRT) is unclear. Several studies have suggested a female advantage in the prognosis of solid tumors. We investigated the relationship between gender differences and disease outcome in NPC patients treated with IMRT in South China.

Methods: A total of 299 patients with non-disseminated NPC were analyzed retrospectively. IMRT was delivered with a simultaneous modulated, accelerated radiotherapy boost technique at prescribed doses of 70 Gy/30 fractions/6 weeks to the primary tumor (GTVp) and positive neck nodes (GTVn), 60Gy (2.0 Gy/day) to the clinical target volume (CTV) and upper neck region and 54 Gy (1.8 Gy/day) to the clinically negative low neck. A median boost dose of 9.2 Gy (4-20 Gy) was administered to patients with persistent disease at the primary site.

Results: With a median follow-up of 52 months, the male patients had a significantly unfavorable 5-year OS (70.7% compared to 94.1%, P < 0.001), DPFS (71.5% compared to 87.3%, P = 0.029) and DMFS (77.2% compared to 89.7%, P = 0.036) than the female patients. In patients younger than 45, the male patients had a poorer 5-year OS (66.8% compared to 91.2%, P = 0.008), DPFS (59.9% compared to 91.2%, P = 0.005) and DMFS (66.4% compared to 94.0%, P = 0.004) than the female patients. For patients older than 45, only the 5-year OS (72.2% compared to 96.0%, P = 0.001) was significantly different.

Conclusions: Gender and age are strong independent prognostic factors for NPC in this study. We are the first to report that younger male patients were more likely to have distant metastases and exhibited inferior overall survival and disease progression-free survival rates compared to other patients.

Show MeSH
Related in: MedlinePlus